Berezin, A.     The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus [Electronic resource] / A. Berezin // Endocrinology & Metabolic Syndrome. - 2016. - Vol. 5, N 1. - 1000217 [pp. 3] . - doi: 10.4172/2161-1017.1000217 Кл.слова (ненормовані): I МЕДИЧНИЙ ФАКУЛЬТЕТ -- ВНУТРІШНІ ХВОРОБИ № 2 -- SCOPUS Анотація: Galectin-3 is a multifunctional chimaera-type β-galactoside binding protein that has been linked to incident Cardiovascular (CV) and renal disease, fibrosis and tissue injury. Elevated level of serum galectin-3 was found in patients with Type 2 Diabetes Mellitus (T2DM) and associate well with CV complications. The short commentary depicts the role of galectin-3 in risk stratification in T2DM individuals. Although perspectives of clinical implementation of galectin-3-guided therapy in T2DM patients are widely discussed, there is evidence regarding cyto-protective role of galectin-3 in diabetes. Whether is rationale to achieve full control under serum galectin-3 as a predictor of successful T2DM treatment is not clear. Further investigations are needed to explain the role of galectin-3 in T2DM development and progression. Есть полнотекстовые версии (для доступа требуется авторизация) Утримувачі документа: * Дод.точки доступу: Березін О. Є.